SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Covalent Group Inc (CVGR) an undiscovered CRO

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: vampire who wrote (64)11/9/1998 11:17:00 AM
From: JanyBlueEyes  Read Replies (1) of 107
 
News - Third Quarter Results

Covalent Group, Inc. Reports Third Quarter Results

WAYNE, Pa., Nov. 9 /PRNewswire/ -- Covalent Group, Inc. (NASDAQ:CVGR)
today announced results for the third quarter ended September 30, 1998. Covalent reported revenues of $2,709,000 and a net loss of $20,000 or $.00 per share. These financial results are in comparison to revenues of $3,545,000 and net income of $322,000 or $.03 per share for the third quarter of last
year.

Bruce LaMont, President and Chief Executive Officer, commented, "The third quarter reflects our continued focus on cost containment with modest growth in revenues over the preceding quarter. Our recent efforts have resulted in converting one of our previously announced letters of intent into an awarded contract. Our outlook for increasing operating profits for the fourth quarter 1998 and 1999 has improved based upon the awarding of a $13.6 million, multiyear, clinical study as announced in the accompanying press release."

Contact Covalent on-line: cracorp.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext